News headlines about Antares Pharma (NASDAQ:ATRS) have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Antares Pharma earned a news impact score of 0.22 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 44.8173719210132 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Antares Pharma (ATRS) traded up 2.05% during trading on Friday, hitting $2.99. 1,059,861 shares of the stock were exchanged. The stock’s market cap is $467.66 million. The stock’s 50 day moving average price is $3.04 and its 200 day moving average price is $2.91. Antares Pharma has a 12 month low of $1.41 and a 12 month high of $3.37.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. The firm had revenue of $13.42 million during the quarter, compared to analysts’ expectations of $12.99 million. Analysts forecast that Antares Pharma will post ($0.11) EPS for the current fiscal year.

ATRS has been the subject of a number of recent research reports. Vetr raised shares of Antares Pharma from a “hold” rating to a “buy” rating and set a $3.30 price objective for the company in a research report on Wednesday, July 5th. Chardan Capital initiated coverage on shares of Antares Pharma in a research note on Friday, June 23rd. They issued a “buy” rating and a $5.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Antares Pharma in a research note on Friday, June 23rd. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Antares Pharma in a research note on Friday, September 8th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $4.34.

WARNING: “Antares Pharma (ATRS) Earning Somewhat Favorable Press Coverage, Report Finds” was originally published by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Insider Buying and Selling by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with's FREE daily email newsletter.